These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 21544950)

  • 1. A diabetes drug, sitagliptin, also has a potential to prevent diabetes.
    Exp Biol Med (Maywood); 2011 Mar; 236(3):xiv. PubMed ID: 21544950
    [No Abstract]   [Full Text] [Related]  

  • 2. Sitagliptin lowers glucagon and improves glucose tolerance in prediabetic obese SHROB rats.
    Chen B; Moore A; Escobedo LV; Koletsky MS; Hou D; Koletsky RJ; Ernsberger P
    Exp Biol Med (Maywood); 2011 Mar; 236(3):309-14. PubMed ID: 21345931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus.
    Aaboe K; Knop FK; Vilsbøll T; Deacon CF; Holst JJ; Madsbad S; Krarup T
    Diabetes Obes Metab; 2010 Apr; 12(4):323-33. PubMed ID: 20380653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Insulin secretion is increased depending on glucose.. Metabolism regulation in type 2 diabetes mellitus over five paths].
    MMW Fortschr Med; 2009 May; 151(19):50. PubMed ID: 19827447
    [No Abstract]   [Full Text] [Related]  

  • 5. Sitagliptin and pioglitazone provide complementary effects on postprandial glucose and pancreatic islet cell function.
    Alba M; Ahrén B; Inzucchi SE; Guan Y; Mallick M; Xu L; O'Neill EA; Williams-Herman DE; Kaufman KD; Goldstein BJ
    Diabetes Obes Metab; 2013 Dec; 15(12):1101-10. PubMed ID: 23782502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Sitagliptine (Januvia): incretin enhancer potentiating insulin secretion for the treatment of type 2 diabetes].
    Scheen AJ; Van Gaal LF
    Rev Med Liege; 2008 Feb; 63(2):105-9. PubMed ID: 18372550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, double-blind, placebo-controlled trial evaluating sitagliptin action on insulin resistance parameters and β-cell function.
    Derosa G; Carbone A; D'Angelo A; Querci F; Fogari E; Cicero AF; Maffioli P
    Expert Opin Pharmacother; 2012 Dec; 13(17):2433-42. PubMed ID: 23061989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Miglitol administered before breakfast increased plasma active glucagon-like peptide-1 (GLP-1) levels after lunch in patients with type 2 diabetes treated with sitagliptin.
    Aoki K; Kamiyama H; Yoshimura K; Shibuya M; Masuda K; Terauchi Y
    Acta Diabetol; 2012 Jun; 49(3):225-30. PubMed ID: 21898126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Variations in inflammatory biomarkers following the addition of sitagliptin in patients with type 2 diabetes not controlled with metformin.
    Derosa G; Carbone A; D'Angelo A; Querci F; Fogari E; Cicero AF; Maffioli P
    Intern Med; 2013; 52(19):2179-87. PubMed ID: 24088749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sitagliptin and metformin--novel combination therapy.
    Seyoum B
    Expert Opin Pharmacother; 2011 Mar; 12(4):641-6. PubMed ID: 21291346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic and pharmacodynamic evaluation of sitagliptin plus metformin.
    Scheen AJ
    Expert Opin Drug Metab Toxicol; 2010 Oct; 6(10):1265-76. PubMed ID: 20707611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short-term efficacy and safety of sitagliptin treatment in long-term stable renal recipients with new-onset diabetes after transplantation.
    Strøm Halden TA; Åsberg A; Vik K; Hartmann A; Jenssen T
    Nephrol Dial Transplant; 2014 Apr; 29(4):926-33. PubMed ID: 24452849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic dipeptidyl peptidase-4 inhibition with sitagliptin is associated with sustained protection against ischemic left ventricular dysfunction in a pilot study of patients with type 2 diabetes mellitus and coronary artery disease.
    McCormick LM; Kydd AC; Read PA; Ring LS; Bond SJ; Hoole SP; Dutka DP
    Circ Cardiovasc Imaging; 2014 Mar; 7(2):274-81. PubMed ID: 24503784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Individualised incretin-based treatment for type 2 diabetes.
    Nauck MA; Meier JJ
    Lancet; 2010 Aug; 376(9739):393-4. PubMed ID: 20580425
    [No Abstract]   [Full Text] [Related]  

  • 15. [New drugs; exenatide and sitagliptin].
    van Bronswijk H; Dubois EA; Pijl H; Cohen AF
    Ned Tijdschr Geneeskd; 2008 Apr; 152(15):876-9. PubMed ID: 18512528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sitagliptin: a novel drug for the treatment of type 2 diabetes.
    Choy M; Lam S
    Cardiol Rev; 2007; 15(5):264-71. PubMed ID: 17700385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sitagliptin or exenatide once weekly for type 2 diabetes: comparison of the clinical trials.
    Doggrell SA
    Expert Opin Pharmacother; 2011 Sep; 12(13):2055-67. PubMed ID: 21534885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term clinical and economic outcomes associated with liraglutide versus sitagliptin therapy when added to metformin in the treatment of type 2 diabetes: a CORE Diabetes Model analysis.
    Lee WC; Samyshkin Y; Langer J; Palmer JL
    J Med Econ; 2012; 15 Suppl 2():28-37. PubMed ID: 22834986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes.
    Herman GA; Bergman A; Stevens C; Kotey P; Yi B; Zhao P; Dietrich B; Golor G; Schrodter A; Keymeulen B; Lasseter KC; Kipnes MS; Snyder K; Hilliard D; Tanen M; Cilissen C; De Smet M; de Lepeleire I; Van Dyck K; Wang AQ; Zeng W; Davies MJ; Tanaka W; Holst JJ; Deacon CF; Gottesdiener KM; Wagner JA
    J Clin Endocrinol Metab; 2006 Nov; 91(11):4612-9. PubMed ID: 16912128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sitagliptin: profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes (update).
    Gallwitz B
    Drugs Today (Barc); 2007 Nov; 43(11):801-14. PubMed ID: 18174966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.